Protech Home Medical is Proud to be Named to the 2020 TSX Venture 50 Group of Top Performing Companies
24 Fevereiro 2020 - 10:00AM
Protech Home Medical Corp. (the “
Company”) (TSXV:
PTQ), a healthcare services company with operations in the U.S.,
is pleased to announce it has been named to the 2020 TSX Venture
50™. This is the TSX Venture Exchange’s annual ranking of top
performing companies on the TSX Venture Exchange. Each of the top
10 companies in each of five major industry sectors have been
identified as leaders in creating shareholder value based on three
key criteria: share price appreciation, market capitalization
growth and trading volume. There are over of 1,600 companies listed
on the TSX Venture Exchange.
“2019 was a dynamic year for us, we strengthened
our core business, developed more sales personnel, established
strong scalable business processes, and completed two accretive
acquisitions,” commented Greg Crawford, Chairman and Chief
Executive Officer of the Company. “We are honored to be recognized
and named to the TSX Venture 50 which serves as confirmation that
our three-pronged strategy is positioning our company and
shareholders for success. With acceleration of growth through our
existing customer base and new acquisition opportunities, as well
as a laser focus on sustainable margin expansion , our outlook for
2020 and beyond is extremely positive and we are excited to share
all of our developments with our current and future shareholders.
I’d like to thank the entire Protech team for their tireless
efforts and its stakeholders for all their continued support.”
The Company is featured in a TSX Venture 50
video available at http://bit.ly/tsxptq.
ABOUT PROTECH HOME MEDICAL
The Company provides in-home monitoring and
disease management services for patients in the United States
healthcare market. It seeks to continue to expand its offerings to
include the management of several chronic disease states focusing
on patients with heart or pulmonary disease, sleep disorders,
reduced mobility and other chronic health conditions. The primary
business objective of the Company is to create shareholder value by
offering a broader range of services to patients in need of in-home
monitoring and chronic disease management. The Company’s organic
growth strategy is to increase annual revenue per patient by
offering multiple services to the same patient, consolidating the
patient’s services and making life easier for the patient.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-Looking Statements
Certain statements contained in this press
release constitute "forward-looking information" as such term is
defined in applicable Canadian securities legislation. The words
"may", "would", "could", "should", "potential", "will", "seek",
"intend", "plan", "anticipate", "believe", "estimate", "expect" and
similar expressions as they relate to the Company,; are intended
to identify forward-looking information. All statements other than
statements of historical fact may be forward-looking information.
Such statements reflect the Company's current views and intentions
with respect to future events, and current information available
to the Company, and are subject to certain risks, uncertainties and
assumptions.. Many factors could cause the actual results,
performance or achievements that may be expressed or implied by
such forward-looking information to vary from those described
herein should one or more of these risks or uncertainties
materialize. Examples of such risk factors include, without
limitation: credit; market (including equity, commodity, foreign
exchange and interest rate); liquidity; operational (including
technology and infrastructure); reputational; insurance; strategic;
regulatory; legal; environmental; capital adequacy; the general
business and economic conditions in the regions in which the
Company operates; the ability of the Company to execute on key
priorities, including the successful completion of acquisitions,
business retention, and strategic plans and to attract, develop and
retain key executives; difficulty integrating newly acquired
businesses; the ability to implement business strategies and pursue
business opportunities; low profit market segments; disruptions in
or attacks (including cyber-attacks) on the Company's information
technology, internet, network access or other voice or data
communications systems or services; the evolution of various types
of fraud or other criminal behavior to which the Company is
exposed; the failure of third parties to comply with their
obligations to the Company or its affiliates; the impact of new and
changes to, or application of, current laws and regulations;
decline of reimbursement rates; dependence on few payors; possible
new drug discoveries; a novel business model; dependence on key
suppliers; granting of permits and licenses in a highly regulated
business; the overall difficult litigation environment, including
in the U.S.; increased competition; changes in foreign currency
rates; increased funding costs and market volatility due to market
illiquidity and competition for funding; the availability of funds
and resources to pursue operations; critical accounting estimates
and changes to accounting standards, policies, and methods used by
the Company; and the occurrence of natural and unnatural
catastrophic events and claims resulting from such events; as well
as those risk factors discussed or referred to in the Company’s
disclosure documents filed with the securities regulatory
authorities in certain provinces of Canada and available at
www.sedar.com. Should any factor affect the Company in an
unexpected manner, or should assumptions underlying the
forward-looking information prove incorrect, the actual results or
events may differ materially from the results or events predicted.
Any such forward-looking information is expressly qualified in its
entirety by this cautionary statement. Moreover, the Company does
not assume responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release and the Company undertakes no obligation to publicly
update or revise any forward-looking information, other than as
required by applicable law.
For further information please visit our website
at www.protechhomemedical.com, or contact:
Gregory CrawfordChief Executive OfficerProtech
Home Medical Corp.859-300-6455investorinfo@myphm.com
Investor Relations:Oak Hill Financial
Inc.Jonathan L. Robinson
CFA416-669-1001jrobinson@oakhillfinancial.ca
Protech Home Medical (TSXV:PTQ)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Protech Home Medical (TSXV:PTQ)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025